Peptide cycling is a convention borrowed from steroid and SARM culture

Where did peptide cycling come from?

Peptide cycling comes from anabolic steroid and SARM culture, where cycling addresses a real problem: suppression of the body's own hormone production.

Exogenous androgens suppress the hypothalamic-pituitary-testicular axis, and the body's own testosterone production drops while the drug is present. A break lets that axis recover before it is suppressed again. That is a specific mechanism tied to a specific hormone system.

Do BPC-157, TB-500 and copper peptides need cycling?

BPC-157, TB-500 and copper peptides have no established reason to be cycled: none of them suppresses endogenous hormone production by any documented mechanism. Most peptides marketed in wellness and recovery contexts do not act through the hypothalamic-pituitary-testicular axis at all, so the entire reason steroid users cycle does not exist for them.

Tissue-repair peptides have no documented receptor-tolerance mechanism either. No documented mechanism supports cycling them at all, let alone on a four-week timer.

When a clinic page or forum post applies "4 on, 4 off" to one of these compounds and cites "avoiding downregulation," it borrows the vocabulary of a different drug class's problem. It then attaches that problem to a compound that does not have it by any established mechanism. BPC-157's human evidence is covered separately.

Does receptor desensitization justify cycling growth hormone secretagogues?

Receptor desensitization is real pharmacology, and growth hormone secretagogues are the peptide class where it is most plausible, but the human evidence for a fade is mixed.

When a molecule repeatedly activates a cell-surface receptor, especially a G-protein-coupled receptor, the cell can respond by reducing receptor sensitivity or number over time. That is textbook pharmacology, not folklore, and it is the one place where "your body adapts" has real biological teeth.

Growth hormone secretagogues act on the ghrelin receptor to stimulate growth hormone release, which makes them the peptide class where this concern is most plausible on paper. For them, cycling is at least mechanistically coherent as a hedge against receptor tolerance. A plausible mechanism and a demonstrated effect at typical human doses are different things.

Shorter human studies of certain related compounds have raised the possibility of an attenuated response to repeated dosing. That remains an open question in the literature, with no settled figure attached to it.

Does MK-677 stop working with continuous use?

MK-677 kept its effect through two years of continuous daily dosing in the Nass et al. trial ^[6]. Healthy older adults took the oral ghrelin mimetic daily for two full years, and growth hormone secretion and IGF-1 levels remained elevated relative to placebo across that period, without the fade a straightforward desensitization model would predict ^[6].

That is one compound and one trial, and it does not settle the question for every secretagogue on the market. It does mean the two-year continuous data that exist do not support the idea that four weeks is when things start to break down. Two years of daily MK-677 showed none of the attenuation that would justify picking four weeks over eight, twelve, or continuous use ^[6].

The MK-677 evidence covers what that IGF-1 rise means for outcomes.

Why is the standard cycle 4 weeks on, 4 weeks off?

The 4-on, 4-off schedule is a convention: no study ties the 4-week figure or the 8-week total to a measured effect in any peptide.

When a source says "eight weeks," it is almost always describing the same 4-on, 4-off pattern counted as a full cycle, not a separately derived figure. No study has measured outcomes at an eight-week mark for any of these peptides and found that something meaningful happens there. The number survives because it sounds specific enough to be mistaken for a finding.

Has any trial compared continuous and cycled peptide dosing?

No published randomized trial has compared continuous dosing with a 4-on, 4-off schedule, on any outcome, for BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, or any other commonly cycled peptide.

The absence is not proof that continuous dosing is fine. It is proof that "4 weeks on, 4 weeks off" was never derived from an experiment on these compounds; it was asserted, and repeated. The ipamorelin evidence covers one of those compounds in detail.

What does a real dosing-schedule trial look like?

Real dosing-schedule trials randomize patients to continuous or intermittent dosing and measure hard outcomes; they exist for loop diuretics and vancomycin ^[1]⁠^[2]⁠^[3]⁠^[4]⁠^[5]⁠^[7], not for the commonly cycled peptides.

Randomized comparisons of continuous versus intermittent infusion exist for loop diuretics in heart failure ^[1], for vancomycin in adults, infants, and critically ill children ^[2]⁠^[3]⁠^[4]⁠^[7], and for prophylactic antibiotic dosing in preterm infants ^[5]. These trials measure hard outcomes, such as drug concentrations, kidney injury, and treatment failure, not impressions.

The results differ by drug and population. Continuous vancomycin infusion reached target concentrations faster and with fewer dose adjustments than intermittent dosing in young infants ^[3]. For loop diuretics, the two strategies performed comparably on the outcomes measured ^[1]. Those findings belong to their drug classes and do not transfer to peptides.

What peptide dosing research tests covers study designs in more depth.

What is still unknown about peptide cycling?

Three questions about peptide cycling remain open:

• Continuous versus cycled. No published trial compares continuous dosing against a fixed on/off schedule for any of the peptides most commonly cycled by convention.
• Desensitization. Whether desensitization, where it is plausible at all, reaches a clinically meaningful magnitude at typical human doses over weeks rather than years is unresolved.
• Off periods. Whether any specific "off" duration restores anything measurable has not been tested for these compounds.

Until that trial exists, a cycling schedule is a scheduling habit, not a dosing instruction backed by data.